All
FDA Approves Keytruda for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma
October 15th 2020Data from the trial that led to the FDA approval demonstrated that Keytruda reduced the risk of progression or death in patients with relapsed or refractory classical Hodgkin lymphoma by 35%, compared to Adcetris.
Mortality From COVID-19 Increases in Patients Receiving Systemic Cancer Treatments
October 14th 2020In an interview with CURE®, Dr. Trisha Wise-Draper discusses new findings that show an increased mortality risk for patients with cancer receiving systemic treatments who subsequently contracted COVID-19.
Dose-Dense Chemotherapy Improves Disease-Free Survival in HR+/HER2- Breast Cancer
October 13th 2020Researchers found that neoadjuvant chemotherapy with intense dose-dense Ellence (epirubicin), Taxol (paclitaxel), and Cytoxan (cyclophosphamide) (iddEPC) demonstrated significant disease-free survival benefits in the treatment of patients with HR+/HER2- breast cancer.
The Role of Surgery in Prostate Cancer Treatment
October 12th 2020Some patients are better suited for surgery than others. In general, patients with widespread metastatic disease are also not good candidates for surgery, particularly if their cancer has spread beyond the prostate to areas like the liver, lungs, and bones.
Cancer Treatment-Induced Dry Mouth is ‘Much More Consequential Than It Sounds’
October 9th 2020Cancer-treatment induced dry mouth can lead to several severe health issues. Here, Dr. Randy Kimple discusses how the side effect can lead to dental health issues, as well as other health consequences including pneumonia.